Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its ...

A genome is the complete set of genetic material in an organism. It contains all the information needed for the growth, ...

Illumina to release new version of its flagship cancer research assay, TruSight Oncology 500 v2: San Diego Thursday, November 21, 2024, 16:00 Hrs [IST] Illumina, Inc., a global le ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will ...

The Institute of Genomics and Global Health, formerly known as the African Centre of Excellence for Genomics of Infectious ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

The Institute of Genomics and Global Health (IGH) at Redeemer’s University in Ede, Osun State, has successfully sequenced a ...

Illumina plans for the global rollout of TruSight Oncology 500 v2, a new version of its NGS cancer assay, by mid-2025.

The Institute of Genomics and Global Health (IGH), formerly known as African Centre of Excellence for Genomics of Infectious ...